NASDAQ:NVNO

enVVeno Medical Q4 2024 Earnings Results & Report

enVVeno Medical logo
$5.77 -0.18 (-3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$5.76 0.00 (-0.09%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

enVVeno Medical beat analyst earnings expectations in its Q4 2024 results, released February 27, 2025. The company reported EPS of -$10.50 versus the -$12.25 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

enVVeno Medical EPS Results

Actual EPS
-$10.50
Consensus EPS
-$12.25
Beat/Miss
Beat by +$1.75
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

enVVeno Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

enVVeno Medical Q4 2024 Earnings FAQ

enVVeno Medical (NASDAQ:NVNO) reported earnings of -$10.50 per share for Q4 2024, beating the consensus estimate of -$12.25. The report was announced on Thursday, February 27, 2025.

enVVeno Medical Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More enVVeno Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enVVeno Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enVVeno Medical and other key companies, straight to your email.

About enVVeno Medical

enVVeno Medical (NASDAQ:NVNO) is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart.

The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition.

Previously known as Hancock Jaffe Laboratories, the company adopted the enVVeno Medical name in 2021. It is based in Irvine, California, and its development efforts are directed primarily toward the U.S. market.

View enVVeno Medical Profile